May 18, 2020

Inari Medical Plans Initial Public Offering

May 18, 2020—Inari Medical, Inc. announced that it will conduct an initial public offering (IPO) of shares of its common stock and has launched a roadshow promoting the IPO.

Inari is a commercial-stage medical device company based in Irvine, California, focused on the treatment of venous diseases. The company has developed two catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system has received 510(k) clearance by the FDA for thrombectomy in the peripheral vessels to treat deep vein thrombosis. The FlowTriever system is cleared for the treatment of pulmonary embolism.

Inari's IPO, which is expected to be priced between $14.00 and $16.00 per share, will be composed of 7,333,000 shares of common stock. In addition, Inari expects to grant the underwriters a 30-day option to purchase up to an additional 1,099,950 shares of its common stock. The Inari shares are expected to trade on the Nasdaq Global Market under the symbol “NARI.” The proposed offering will be made by prospectus available from Bank of America Securities and Morgan Stanley. A registration statement relating to these securities has been filed with the US Securities and Exchange Commission but has not yet become effective, advised the company.


May 19, 2020

Two-Year ALPS Registry Outcomes Published for LimFlow pDVA System

May 15, 2020

Colorado Study Uses Thromboelastography to Identify Clot Risk in COVID-19 Patients